# Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

> **NCT06535607** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 257 (estimated)

## Conditions studied

- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
- Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
- Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

## Interventions

- **BIOLOGICAL:** Volrustomig
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT06535607
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 257 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06535607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06535607, "Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06535607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*